H.C. Wainwright Reiterates a Buy on Delcath Systems (DCTH), Lowers the PT

​Delcath Systems, Inc. (NASDAQ:DCTH) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 5, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Delcath Systems, Inc. (NASDAQ:DCTH), but lowered the price target from $31 to $30.

​Earlier on November 4, Delcath Systems, Inc. (NASDAQ:DCTH) released results for its fiscal Q3 2025. The company posted a revenue of $20.6 million, up from $11.2 million last year. Moreover, the EPS came in at $0.02, ahead of the consensus by $0.08. Management attributed revenue growth to HEPZATO KIT and CHEMOSAT revenues. The HEPZATO KIT revenue grew to $19.3 million from $10 million year-over-year, and CHEMOSAT revenue increased from $1.2 million in Q3 2024 to $1.3 million in the latest quarter. Notably, the gross margins also improved from 85% to 87% during the same time.

​However, despite the strong performance, management lowered the full-year revenue guidance and now expects it to be in the range of $83 million to $85 million, down from the previous range of $93 million to $96 million. Management noted that this is due to a slowdown in new patient starts, partially due to summer seasonality.

Delcath Systems, Inc. (NASDAQ:DCTH) is a healthcare company specializing in interventional oncology treatments for liver cancers. Its main products include the HEPZATO KIT and CHEMOSAT Hepatic Delivery System.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.